Regulatoriskt pressmeddelande

Active Biotech Interim Report Q1 2023

Active Biotech

Ladda ner börsmeddelandet

FIRST QUARTER IN BRIEF

Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30)

Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances

New preclinical data on naptumomab published

EVENTS AFTER THE END OF THE PERIOD

Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)

New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023 (April 27)

FINANCIAL SUMMARY

SEK M	Jan-Mar		Full year
	2023	2022	2022
Net sales	-	-	-
Operating profit/loss	-11.8	-15.3	-57.9
Profit/loss after tax	-11.5	-15.7	-58.4
Earnings per share (SEK)	-0.04	-0.07	-0.25
Cash and cash equivalents (at close of period)	30.2	37.8	41.8

The report is also available at www.activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.